Idarubicin Accord (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and blocks the enzyme topoisomerase II, preventing the re‑ligation of DNA strands during replication. This causes double‑strand breaks, halting cell division and triggering programmed cell death of rapidly proliferating leukemic cells.

The dosage of Idarubicin Accord is individualized by the prescribing oncologist based on factors such as disease stage, patient weight, renal and hepatic function, and prior therapy. Only a qualified healthcare professional should determine the appropriate regimen.

Idarubicin is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and be excreted in breast milk, posing a risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period thereafter.

To place an order, submit an enquiry on the Idarubicin Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Idarubicin belongs to the anthracycline class and is often compared with daunorubicin or idarubicin‑based regimens. It generally offers a similar efficacy profile but may have a slightly different toxicity spectrum, such as reduced cardiotoxicity at equivalent doses, making it a preferred option in some protocols.

Idarubicin Accord should be stored refrigerated between 2 °C and 8 °C, protected from light, and never frozen or shaken. The product must be kept in its original packaging until preparation, and reconstituted solutions should be used promptly according to the manufacturer’s instructions.

Idarubicin Accord is given by intravenous infusion, typically over 30–60 minutes, under the supervision of qualified medical staff. The infusion rate and total dose are determined by the treating physician and may be adjusted based on patient tolerance and laboratory monitoring.

The most serious risks include cardiotoxicity leading to heart failure, severe myelosuppression with risk of infection or bleeding, and the rare development of secondary acute leukemia. Continuous cardiac monitoring and regular blood counts are essential to detect these complications early.

Idarubicin should be avoided in patients with known hypersensitivity to anthracyclines, pre‑existing severe cardiac disease, uncontrolled infections, or those who are pregnant or breastfeeding. It is also contraindicated in individuals with inadequate bone‑marrow reserve unless benefits outweigh risks.